Airway hyperresponsiveness in asthma : the role of the epithelium
Copyright © 2024. Published by Elsevier Inc..
Airway hyperresponsiveness (AHR) is a key clinical feature of asthma. The presence of AHR in people with asthma provides the substrate for bronchoconstriction in response to numerous diverse stimuli, contributing to airflow limitation and symptoms including breathlessness, wheeze and chest tightness. Dysfunctional airway smooth muscle (ASM) significantly contributes to AHR and is displayed as increased sensitivity to direct pharmacological bronchoconstrictor stimuli, such as inhaled histamine and methacholine (direct AHR), or to endogenous mediators released by activated airway cells such as mast cells (indirect AHR). Research in in vivo human models has shown that the disrupted airway epithelium plays an important role in driving inflammation that mediates indirect AHR in asthma, through the release of cytokines such as TSLP and IL-33. These cytokines upregulate type 2 cytokines promoting airway eosinophilia and induce the release of bronchoconstrictor mediators from mast cells such as histamine, prostaglandin D2 and cysteine leukotrienes. While bronchoconstriction is largely due to ASM constriction, airway structural changes termed 'remodelling', likely mediated in part by epithelial-derived mediators, also lead to airflow obstruction and may enhance AHR. In this review, we outline the current knowledge of the role of the airway epithelium in AHR in asthma and its implications on the wider disease. Increased understanding of airway epithelial biology may contribute to better treatment options, particularly in precision medicine.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
The Journal of allergy and clinical immunology - (2024) vom: 21. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bradding, Peter [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Airway hyperresponsiveness |
|---|
| Anmerkungen: |
Date Revised 23.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.jaci.2024.02.011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368850684 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368850684 | ||
| 003 | DE-627 | ||
| 005 | 20240229150710.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jaci.2024.02.011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1304.xml |
| 035 | |a (DE-627)NLM368850684 | ||
| 035 | |a (NLM)38395082 | ||
| 035 | |a (PII)S0091-6749(24)00191-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bradding, Peter |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Airway hyperresponsiveness in asthma |b the role of the epithelium |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 23.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024. Published by Elsevier Inc. | ||
| 520 | |a Airway hyperresponsiveness (AHR) is a key clinical feature of asthma. The presence of AHR in people with asthma provides the substrate for bronchoconstriction in response to numerous diverse stimuli, contributing to airflow limitation and symptoms including breathlessness, wheeze and chest tightness. Dysfunctional airway smooth muscle (ASM) significantly contributes to AHR and is displayed as increased sensitivity to direct pharmacological bronchoconstrictor stimuli, such as inhaled histamine and methacholine (direct AHR), or to endogenous mediators released by activated airway cells such as mast cells (indirect AHR). Research in in vivo human models has shown that the disrupted airway epithelium plays an important role in driving inflammation that mediates indirect AHR in asthma, through the release of cytokines such as TSLP and IL-33. These cytokines upregulate type 2 cytokines promoting airway eosinophilia and induce the release of bronchoconstrictor mediators from mast cells such as histamine, prostaglandin D2 and cysteine leukotrienes. While bronchoconstriction is largely due to ASM constriction, airway structural changes termed 'remodelling', likely mediated in part by epithelial-derived mediators, also lead to airflow obstruction and may enhance AHR. In this review, we outline the current knowledge of the role of the airway epithelium in AHR in asthma and its implications on the wider disease. Increased understanding of airway epithelial biology may contribute to better treatment options, particularly in precision medicine | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Asthma | |
| 650 | 4 | |a airway hyperresponsiveness | |
| 650 | 4 | |a bronchoconstriction | |
| 650 | 4 | |a cytokines | |
| 650 | 4 | |a epithelium | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a mast cells | |
| 650 | 4 | |a respiratory | |
| 700 | 1 | |a Porsbjerg, Celeste |e verfasserin |4 aut | |
| 700 | 1 | |a Côté, Andréanne |e verfasserin |4 aut | |
| 700 | 1 | |a Dahlén, Sven-Erik |e verfasserin |4 aut | |
| 700 | 1 | |a Hallstrand, Teal S |e verfasserin |4 aut | |
| 700 | 1 | |a Brightling, Christopher E |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of allergy and clinical immunology |d 1971 |g (2024) vom: 21. Feb. |w (DE-627)NLM000018449 |x 1097-6825 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:21 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jaci.2024.02.011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 21 |c 02 | ||